144163-97-3

Basic information

• Product Name: ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate
• Synonyms: [(5-Thiazol)Methyl]-(4-nitrophenyl)carbonate;((5-thiazolyl)Methyl)-(4-nitrophenyl)carbonate (SC);5-(p-NitrophenoxycarbonyloxyMethyl);NCT;RITONAVIR INTERMEDIATE-A THIOZOLE [CARBONIC ACID-4NITROPHENYL-5-THIAZOLYLMETHYLESTER (NCT);4-Nitrophenyl (thiazol-5-ylMethyl) carbonate;((5-Thiazolyl)methyl)-(4-nitrophenyl)carbote;carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester
• CAS NO: 144163-97-3
• Molecular Formula: C₁₁H₈N₂O₅S
• Molecular Weight: 280.26
• EINECS: 1806241-263-5
• Product Categories: API intermediates;Heterocyclic Compounds;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Ritonavir
• Mol File: 144163-97-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 65-67°C
• Boiling Point: 475.333 °C at 760 mmHg
• Flash Point: 241.273 °C
• Appearance: pale-yellow solid
• Density: 1.485
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Ethyl Acetate (Slightly)
• PKA: 1.86±0.10(Predicted)
• CAS DataBase Reference: ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate(CAS DataBase Reference)
• NIST Chemistry Reference: ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate(144163-97-3)
• EPA Substance Registry System: ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate(144163-97-3)

Safety Data

• Hazardous Substances Data: 144163-97-3(Hazardous Substances Data)

Usage

Chemical Properties

Pale-Yellow Solid

Uses

Different sources of media describe the Uses of 144163-97-3 differently. You can refer to the following data:
1. Retinovir intermediate
2. Retinovir intermediate.

InChI:InChI=1/C11H8N2O5S/c14-11(17-6-10-5-12-7-19-10)18-9-3-1-8(2-4-9)13(15)16/h1-5,7H,6H2

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 109-02-4 4-methyl-morpholine 
• 38585-74-9 thiazol-5-yl-methanol 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 

Downstream Products

• 144164-11-4 (2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-3-hydroxy-1,6-diphenylhexane 
• 1004316-18-0 C₂₃H₂₇N₃O₂S 
• 1004316-72-6 C₁₉H₂₇N₃O₂S 
• 1004316-71-5 C₁₉H₂₇N₃O₂S 
• 1004316-78-2 C₂₃H₂₇N₃O₂S 
• 162849-95-8 (2S,3S,5S)-5-(t-butyloxycarbonylamino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-3-hydroxy-1,6-diphenylhexane 
• 155213-67-5 ritonavir 
• 1169870-36-3 C₃₆H₄₅N₇O₅S₂ 
• 1169870-34-1 C₃₆H₄₆N₆O₄S₂ 
• 1169870-18-1 C₃₉H₅₁N₇O₅S₂ 
• 1247119-33-0 N-((1R,4R)-4-amino-5-phenyl-1-benzylpentyl)carbamic acid 5-thiazolylmethyl ester hydrochloride 

Relevant articles and documents

Design and synthesis of selenazole-substituted ritonavir analogs

With the help of Surflex-Dock calculation, two ritonavir analogs in which one thioazole unit was replaced by selenazole have been designed and synthesized. The key selenazole structure was constructed from β-azido diselenide through a cascade diselenide cleavage/selenocarbonylation/Staudinger reduction/aza-Wittig reaction and a following MnO2 oxidation. The accordingly prepared compounds exhibited good anti-HIV-1 (IIIB) activities comparable to that of the original ritonavir, as well as the positive SI values.

INHIBITORS OF CYTOCHROME P450

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.